Fortified antibiotic agents are needed for the management of keratitis

Article

An investigation in the Journal of Cataract and Refractive Surgery strongly suggests the use of fortified antibiotic agents for prevention of vision loss in infectious keratitis patients.

An investigation in the Journal of Cataract and Refractive Surgery strongly suggests the use of fortified antibiotic agents for prevention of vision loss in infectious keratitis patients.

Dr Vitoria de Rojas et al., Instituto Oftalmológico Europeo, Coruña, Spain, conducted a multicentred case series study on 9794 patients with infectious keratitis who underwent surface ablation between January 2003 and December 2009. The main outcome measures included incidence of infectious keratitis after surface ablation, ulture results, response to treatment, and visual outcomes. The team recorded incidence, risk factors, clinical course, days to diagnosis, medical and surgical treatment, and visual outcome.

Infectious keratitis after surface ablation was found in 39 eyes of 38 patients and the onset of infection occurred within 7 days of surgery in 28 cases. From the samples taken it was found that 13 of 27 cases had positive cultures- with the most frequent microorganism being the Staphylococcus species in 9 patients.

In 23 patients the final corrected distance visual acuity (CDVA) was 20/20 or better, 20/40 or better in 36 patients and worse then 20/40 in 3 patients. The occurrence of infectious keratitis after surface ablation was 0.20% and was considered potentially sight threatening.

The study suggested the immediate use of fortified antibiotic agents for the management of infectious keratitis- meaning vision is more likely to be preserved in most incidences.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.